GSK launches $2.5 bln buyback, lifts sales target after stellar Q4

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make up for pressures on its vaccines revenue.

GSK’s shares were up 6% at 1342 GMT after the British…